KRAKOW, Poland, April 27,
2020 /PRNewswire/ -- Selvita S.A. (WSE: SLV) - one of the
largest preclinical contract research organizations in Europe, has signed a grant agreement with the
National Centre for Research and Development for the development of
a cell-based phenotypic platform based on high content imaging
system integrated with artificial intelligence data analysis for
multiple therapeutic areas, including neuroinflammatory and
fibrosis drug discovery (HiScAI - High Content Screening Artificial
Intelligence).
The grant will be executed in a consortium with Ardigen –
bioinformatics company harnessing advanced Artificial Intelligence
methods for novel precision medicine.
This grant provides Selvita and Ardigen with almost EUR 1.05 million of non-dilutive financing. Total
net value of the project amounts to EUR 1.85
million and the anticipated project duration is over the
next three years.
Selvita and Ardigen will create the HiScAI Technology Platform,
dedicated to the study of phenotypic changes in cells treated
with a drug candidate, using machine learning and artificial
intelligence to analyze the data from HCS. The platform will be
used to test new drugs in multiple therapeutic areas, including
neuroinflammatory and fibrotic diseases, as well as other,
addressing specific limitations of existing therapeutic
approaches.
Selvita will be responsible for the development of two sets of
cellular tests from specified therapeutic areas capable of
generating images for artificial intelligence system analysis. The
phenotypic changes in the cells will be analyzed using the HCS
technology.
The HiScAl Technology Platform created in cooperation with
Ardigen will allow us to complement our integrated drug discovery
portfolio of services with a new, powerful method to discover and
develop new drugs in a fast and effective manner. We hope, that for
our customers, this can be a step forward to acceleration of the
nomination of clinical candidates in areas of high unmet medical
needs – said Edyta Jaworska,
Management Board Member, Integrated Drug Discovery at Selvita.
Within this project, Ardigen will develop an advanced Computer
Vision platform that enables fast
and precise inference on images streaming from HCS platform
Data from high-content screens are a rich source of
information. Advanced machine learning methods allow to detect
image-based signatures of compounds, diseases, or genes. The HCS
platform will empower researchers in drug discovery - comments
director of Ardigen AI Labs - Michał Warchoł, Ph.D.
Development of the platform will strengthen Selvita's and Ardigen's
technological offer aimed at pharmaceutical and biotechnology
companies aiming to accelerate their drug discovery efforts with
the use of Artificial Intelligence.
About Selvita
Selvita is an integrated service company providing
multidisciplinary support in resolving the unique challenges of
research within area of drug discovery, regulatory studies, as well
as research and development.
The company was established in 2007 and currently employs almost
500 professionals, of which over 1/3 hold PhD title. Selvita is
headquartered in Krakow,
Poland, with a second research
site in Poznan, Poland and foreign
offices located in Cambridge, MA
and South San Francisco, in the U.S., as well as in Cambridge, UK. The company has a proven track
record of successfully completed projects and customers in 40
countries. Majority of Company revenues come from pharma, biotech
and agro-chemical companies from the US and Europe. Selvita is listed on the Warsaw Stock
Exchange (WSE: SLV).
About Ardigen
Ardigen is harnessing advanced Artificial Intelligence methods
for novel precision medicine. The company accelerates therapy
development by decoding microbiome, designing immunity and
providing digital drug discovery services. Ardigen's team is rooted
in biology and holds deep expertise in bioinformatics, machine
learning, and software engineering. The company's in-house datasets
together with platforms for immunology, biomarker, and microbiome
research can empower effective pharmaceuticals development.
Contacts:
Natalia Baranowska| Selvita S.A.
+48-784-069-418
natalia.baranowska@selvita.com
Barbara Wyroba | Ardigen S.A.
+48-539-730-118
barbara.wyroba@ardigen.com
View original
content:http://www.prnewswire.com/news-releases/selvita-and-ardigen-will-receive-funding-for-the-development-of-an-ai-based-high-content-screening-platform-301047385.html
SOURCE Selvita
